Picture of Biomarin Pharmaceutical logo

BMRN Biomarin Pharmaceutical Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Annual cashflow statement for Biomarin Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-117-77.2-23.8859-64.1
Depreciation
Deferred Taxes
Non-Cash Items69.9120151234210
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-94-49.4-101-22466
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-8.7620.248.385.4305
Capital Expenditures-199-145-163-138-119
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-10640913283.9-247
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities-305264-31-53.6-366
Financing Cash Flow Items-35.4-80.5-101-44.6-46.2
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities507-388-74.7181-0.048
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash190-104-56.5212-61.9

Or unlock with your email

Or unlock with your email